A letter from a pharmaceutical representative to the National Assembly affected the process of the National Assembly's Health and Welfare Committee's handling of generics, drug for data-based re-evaluation "1+3 bill."

It was reflected in the revised schedule when a representative of company A sent a petition to 24 members of the National Assembly's Health and Welfare Committee that IMD, which has decided to jointly develop more than four pharmaceutical companies, could have a negative impact on development and launch.

The Pharmaceutical Affairs Law, approved by the National Assembly's Health and Welfare Committee on the 16th, contains the effective date, application case, and progress mea